Molecular biology

Study Illustrates Zeropollution's Enhancing Skin's Resilience to Environmental Damage

Retrieved on: 
Tuesday, March 5, 2024
Quercetin, Lippia, Air pollution, Woman, Capsule, Elasticity, Doctor of Philosophy, Oleuropein, Rosmarinus, Aryl hydrocarbon receptor, Inflammation, Free-radical theory of aging, Pollution, HPLC, Heart rate, Skin, Volunteering, Molecular biology, Radiation, Health, Lipid peroxidation, Caturla, Hesham Tillawi, Sophora, Drink, Reactive oxygen species, Journal, Clinical trial, Oxidative stress, ROS, Endothelium, Tissue, Núria, Antioxidant, DNA, Beauty, Dietary supplement

MADRID, March 5, 2024 /PRNewswire/ -- A new, preclinical study highlights the abilities of a beauty-from-within botanical-blend Zeropollution® to shield skin from the adverse effects of city pollution, especially from free radical damage on a cellular level.

Key Points: 
  • This patented multi-herbal cosmeceutical has been crafted to synergistically strengthen the skin's protective barrier against environmental insults through an "inside out" approach.
  • The study led by Laurent Peno-Mazzarino was published in the Journal of Current Issues in Molecular Biology in January 2024.
  • This encompasses reactive molecules generated by factors such as UV radiation, pollution, and other environmental stressors that can damage cells and tissues.
  • In this study, Zeropollution successfully counteracted the adverse effects of urban dust on the heart rate of zebra fish embryos.

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Retrieved on: 
Tuesday, March 5, 2024
AMSilk, A-DNA, AI, Research and development, Molecular biology, PCT, Patent Cooperation Treaty, Protein engineering, Gold, Gel, Microplastics, CO2, BRAIN, Partnership, Fine chemical

The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.

Key Points: 
  • The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.
  • BRAIN Biotech had already successfully used its protein engineering strategy in the development of a variety of protein and enzyme products in order to tailor them for industrial applications.
  • Pelzer cites powerful bioinformatics including the various AI approaches used by the experienced protein engineering experts at BRAIN Biotech as the basis for protein engineering, tailoring their approach to each specific inquiry.
  • With their years of protein engineering expertise and with our common vision, BRAIN Biotech is an ideal fit as a development partner."

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Retrieved on: 
Tuesday, March 5, 2024
AMSilk, A-DNA, AI, Research and development, Molecular biology, PCT, Patent Cooperation Treaty, Protein engineering, Gold, Gel, Microplastics, CO2, BRAIN, Partnership, Fine chemical

The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.

Key Points: 
  • The success of this strategic R&D collaboration is based on the use of BRAIN Biotech's rational design in protein engineering.
  • BRAIN Biotech had already successfully used its protein engineering strategy in the development of a variety of protein and enzyme products in order to tailor them for industrial applications.
  • Pelzer cites powerful bioinformatics including the various AI approaches used by the experienced protein engineering experts at BRAIN Biotech as the basis for protein engineering, tailoring their approach to each specific inquiry.
  • With their years of protein engineering expertise and with our common vision, BRAIN Biotech is an ideal fit as a development partner."

B&C and Acta Announce Appointment of Mark J. Washko as Senior Government Affairs Advisor, and Alexander E. Howard and Michelle C. Mims to Science Team Positions

Retrieved on: 
Friday, March 1, 2024
National Association, Reno 1868 FC, Commerce, Molecular biology, Consultant, University, ASTM, House, Biophysical chemistry, Energy, EPA, Legislation, Public policy, Representative, Good laboratory practice, Advisory board, Committee, Environmental justice, Federation, College, Bowling Green State University, Quality assurance, Corteva, Majority, Biophysical environment, BASF, Environment, OECD, Business network, TSCA, Sunscreen Innovation Act, Charles River Laboratories, Government, Organization, GLP, Frank, Bachelor, Society, B&C, Policy, American Chemistry Council, Management

WASHINGTON, March 1, 2024 /PRNewswire-PRWeb/ -- Bergeson & Campbell, P.C. (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of several professionals to key roles at our firms.

Key Points: 
  • (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of Mark J. Washko, Alexander E. Howard, and Michelle C. Mims to key roles at our firms.
  • (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of several professionals to key roles at our firms.
  • Mr. Washko, Mr. Howard, and Ms. Mims join a powerful team of advocates, scientists, and regulatory and business consultants at B&C and Acta.
  • Mr. Washko, Mr. Howard, and Ms. Mims join a powerful team of advocates, scientists, and regulatory and business consultants at B&C and Acta.

Circular Genomics Strengthens Leadership Team with Key Commercial and Research Hires

Retrieved on: 
Monday, February 26, 2024
SSRI, Senior, Champaign–Urbana metropolitan area, Green belt, Management, Clinical research, Kellogg School of Management, MBA, Molecular biology, Psychiatry, Miami University, University, Hologic, RNA, Society, Biomarker, DSM-IV codes, Medicine, Technologist, Novartis, Neurology, Genomics, Exact sciences, IVD

ALBUQUERQUE, N.M., Feb. 26, 2024 /PRNewswire/ -- Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the appointments of Dave Karlander as Chief Commercial Officer and Vishi Srinivasan, Ph.D., as Senior Director of Clinical Research. In these new roles, Karlander will oversee and manage all commercial aspects of the company's operations, including sales, product marketing and managed care; and Dr. Srinivasan will drive the advancement of Circular Genomics' clinical pipeline and strategy for the development of circular RNA-based tests in psychiatric and neurologic disorders.

Key Points: 
  • ALBUQUERQUE, N.M., Feb. 26, 2024 /PRNewswire/ -- Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the appointments of Dave Karlander as Chief Commercial Officer and Vishi Srinivasan, Ph.D., as Senior Director of Clinical Research.
  • In these new roles, Karlander will oversee and manage all commercial aspects of the company's operations, including sales, product marketing and managed care; and Dr. Srinivasan will drive the advancement of Circular Genomics' clinical pipeline and strategy for the development of circular RNA-based tests in psychiatric and neurologic disorders.
  • "I am delighted to welcome both Dave and Vishi to our leadership team at Circular Genomics," said Dr. Paul Sergeant, Chief Executive Officer of Circular Genomics.
  • "Dave's extensive background in commercial operations, including leading several product launches, will be invaluable during this stage at our company.

XP Health Continues Momentum with New Bell Bank Partnership and Addition of a CMO to its Leadership Roster

Retrieved on: 
Tuesday, February 20, 2024
CFO, SAN, Doctor of Philosophy, DocuSign, AI, STEM, Molecular biology, Partnership, Health, Growth, UV, IPO, University, Bell Bank, Organization, B2B2C, Insurance, Publication, Management

XP Health's vision benefits provide reduced to no-cost frames with a market leading selection.

Key Points: 
  • XP Health's vision benefits provide reduced to no-cost frames with a market leading selection.
  • "Among the great things happening at XP Health is the expansion of our leadership roster with seasoned industry veterans from leading insurance and healthtech organizations.
  • Adding to XP Health's growing appeal and momentum, in fall of 2023 the organization launched a new coverage model.
  • XP Health is reimagining what is possible through its digital-first platform that leverages AI, AR, and customer-centric design.

Candidates’ aging brains are factors in the presidential race − 4 essential reads

Retrieved on: 
Friday, February 16, 2024
Ageing, University, Dementia, Diet, Molecular biology, Friends, Thought, Loss, Conditional sentence, Exercise, Cell, Brandeis, Memory, Swimming, Cognition, Family, Notifiable disease, University of Florida, Biology

The leading contenders in the 2024 presidential election are two of the three oldest people ever to serve as president.

Key Points: 
  • The leading contenders in the 2024 presidential election are two of the three oldest people ever to serve as president.
  • Both Biden and Trump have faced criticism about what can appear to be obvious signs of aging, including questions about their memory and cognitive abilities.
  • Scholars writing for The Conversation U.S. have discussed various aspects of how aging affects people’s brains.
  • Key factors include the strength of a person’s social connections, as well as their sleeping habits, water consumption, exercise and diet.

Tate & Lyle Partners with Cryptobiotix: New ex-vivo study on low and no calorie sweeteners finds positive impact or no impact on human gut microbiota

Retrieved on: 
Thursday, February 15, 2024
Sorbitol, Erythritol, Stevia, Nutrition, Diet, Research, Molecular biology, Microbiota, Food, Potassium, Food science, Tate & Lyle, Drink, Psicose, Canadian International Council, Soft drink

Tate & Lyle PLC (Tate & Lyle), a world leader in ingredient solutions for healthier food and drink, partnered with Cryptobiotix, pioneers in preclinical gastrointestinal research, on the study.

Key Points: 
  • Tate & Lyle PLC (Tate & Lyle), a world leader in ingredient solutions for healthier food and drink, partnered with Cryptobiotix, pioneers in preclinical gastrointestinal research, on the study.
  • The doses of low and no calorie sweeteners used were based on actual intakes, regulations and amounts that are generally included in foods and beverages during different timepoints.
  • Assessments of additional low and no calorie sweeteners, including allulose and erythritol, are being completed and details will be shared in due course.
  • The low and no calorie sweeteners studied for this paper included: Acesulfame potassium (aceK), maltitol, sorbitol, stevia, sucralose and tagatose.

Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors

Retrieved on: 
Thursday, February 15, 2024
Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Other Science, Science, Boston, Champaign–Urbana metropolitan area, Health care, University, Multimedia, Hospital, Access, Boston Consulting Group, Molecular biology, Cellular, Oral medicine, Therapy, Patient, Internal medicine, Massachusetts General Hospital, Phase, Harvard Medical School, Nephrology

Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.

Key Points: 
  • Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.
  • Dr. Becker will serve as a member of the audit committee of the board.
  • View the full release here: https://www.businesswire.com/news/home/20240215803782/en/
    “I am excited that Dan has been appointed to our board,” said Jorge Bartolome, President and Chief Executive Officer of Areteia.
  • and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan and received his B.S.

Reproductive Partners Medical Group, an Ivy Fertility Clinic, Expands With New Providers And New Location

Retrieved on: 
Wednesday, February 14, 2024
Women, Baby, Maternity, Genetics, Biotechnology, Family, Other Health, Managed Care, Health, Consumer, Infertility, Research, Suite, Reproductive medicine, MD, Dartmouth College, Physician, Growth, Molecular biology, Fertility, University, University of California, Davis, Immunology, Patient, University of California, California State University, Heart, Harvard Medical School, UCLA, RPMG, Medical device

Dr. Chang and Dr. Brower are both double board certified reproductive endocrinologists and infertility specialists.

Key Points: 
  • Dr. Chang and Dr. Brower are both double board certified reproductive endocrinologists and infertility specialists.
  • “Reproductive Partners Medical Group has stayed at the forefront of our field by honoring our heritage of excellence while continually looking toward the future,” said Lab Medical Director Gayane Ambartsumyan, MD.
  • She received her medical degree from University of California, Davis, and completed her residency in Obstetrics, Gynecology, and Reproductive Medicine at Harvard Medical School.
  • “This is an exciting time to join Reproductive Partners Medical Group and Ivy Fertility,” said Dr. Brower.